Methylphenidate and Long‐Term Risk of Cardiovascular Diseases: A Nationwide Cohort Study
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70493 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Christelle Berthod und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Investigation Center CIC-1407, UMR 5558, Inserm, Hospices Civils de Lyon, Bron, France. Hauptthemen laut MEDLINE: Methylphenidate, Cardiovascular Diseases, Central Nervous System Stimulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Cardiovascular safety of methylphenidate remains a matter of debate.
Methods
To evaluate the long‐term cardiovascular risk associated with methylphenidate use, a cohort study was conducted using the French National Health Data System. New users were defined by a first methylphenidate dispensation (index date) between January 1, 2014, and December 31, 2023. Each new user was matched with three nonusers by sex and by month and year of birth. Individuals with prior cardiovascular disease or relevant cardiovascular comorbidities were excluded. The primary outcome was cardiovascular disease, defined by International Classification of Diseases codes or antihypertensive drug use. Cox proportional hazards models estimated adjusted hazard ratios (HRs), accounting for demographic and clinical covariates. Negative control outcomes were used to assess residual confounding, allowing the derivation of calibrated HRs and confidence intervals.
Results
A total of 212 216 new users and 636 648 matching nonusers were included. Mean age was 13.7 years and 72% were males. Over a follow‐up of ~4 years, 3858 cardiovascular diseases occurred (0.45%): 1960 in new users (9.2 per 1000) and 1898 in nonusers (3 per 1000). The adjusted HR was 2.37 (95% CI [2.21; 2.54]), with a calibrated HR of 1.85 (95% CI [1.55; 2.21]).
Conclusions
The results suggest that methylphenidate use may be associated with an increased risk of cardiovascular diseases. Although the calibrated estimates indicate attenuation due to residual confounding, the association remained statistically significant. This supports recommendations for cardiovascular monitoring during treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Investigation Center CIC-1407, UMR 5558, Inserm, Hospices Civils de Lyon, Bron, France.
- Pediatric Emergency Unit, Hospices Civils de Lyon, Bron, France.
- Department of General Pediatrics, Hospices Civils de Lyon, Bron, France.
- Department of Anesthesia and Intensive Care, Louis Pradel Cardiology Hospital, Hospices Civils de Lyon, Bron, France.
- Lyon Est Faculty of Medicine, Claude Bernard University Lyon 1, Lyon, France.
- CarMeN Laboratoire, Inserm UMR 1060, Université Claude Bernard Lyon 1, Lyon, France.
ORCID-Profile: Christelle Berthod, Matthias Jacquet-Lagreze, Behrouz Kassaï-Koupai
Zitieren
APA
Berthod, C., Loppinet, T., Ndiaye, M., Boussaha, I., Jacquet-Lagreze, M., & Kassaï-Koupai, B. (2026). Methylphenidate and Long‐Term Risk of Cardiovascular Diseases: A Nationwide Cohort Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70493
Vancouver
Berthod C, Loppinet T, Ndiaye M, Boussaha I, Jacquet-Lagreze M, Kassaï-Koupai B. Methylphenidate and Long‐Term Risk of Cardiovascular Diseases: A Nationwide Cohort Study. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70493
BibTeX
@article{Berthod2026,
author = {Berthod, Christelle and Loppinet, Thomas and Ndiaye, Marietou and Boussaha, Inesse and Jacquet-Lagreze, Matthias and Kassaï-Koupai, Behrouz},
title = {Methylphenidate and Long‐Term Risk of Cardiovascular Diseases: A Nationwide Cohort Study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70493}
}
EUVIMED